UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus ...

This was the stock's third consecutive day of losses.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $190.82, a high estimate of ...

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...

Biogen (NASDAQ:BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ((RNAi)) therapies targeting serious diseases. Under the agreement, City Therapeutics will use its ...

Biogen has highlighted the growing role of felzartamab in its pipeline during a virtual investor seminar, spotlighting three ...

Biogen Inc. is teaming up with a new startup launched by Alnylam Pharmaceuticals’ founding CEO John Maraganore.

Biogen stock was muted Thursday after the biotech company beat Wall Street's first-quarter expectations, including strong sales for newcomer drugs Leqembi and Skyclarys. Leqembi, which partner ...

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

Shares of Biogen Inc. BIIB shed 1.79% to $133.06 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the Dow Jones Industrial Average DJIA remaining mostly ...